Uncoupling Relapse Reduction and Disability Progression

Key Points

• The research aims to assess how tolebrutinib affects disability worsening compared to its impact on relapse prevention in patients with multiple sclerosis.
• Comparative analysis of tolebrutinib and other disease-modifying therapies (DMTs)
• Evaluation of confirmed disability worsening (CDW) rates
• Assessment of relapse prevention efficacy
• Tolebrutinib shows different effects on disability worsening compared to relapse prevention
• Overall improvement in relapse rates was noted, though disability worsening did not align with these effects

Abstract